$2,150,000 of CVS HEALTH (AND SUBSIDIARIES) lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to retail pharmacy, drug pricing, and women's health. H.R. 3164 - The Ensuring Community Access to Pharmacist Services Act of 2025 S. 2426 - The Equitable Community Access to Pharmacist Services Act P.L. 119-21 - The One Big, Beautiful Bill Act - issues related to retail pharmacy Issues related to corporate tax. P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to pharmacy testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. Issues related to Medicaid. S. 882, The Patients Before Middlemen (PBM) Act S. 927, The Protecting Pharmacies in Medicaid Act S. 1105 - No Unreasonable Payments, Coding, Or Diagnoses for the Elderly Act P.L. 119-21 - The One Big, Beautiful Bill Act - - issues related to Medicaid and PBMs H.R. 4317, The Pharmacy Benefit Manager (PBM) Reform Act Issues related to employer, small group and individual insurance markets. H.R. 2214, the Delinking Revenue from Unfair Gouging (DRUG) Act P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 5433 - The Patients Over Profits Act S. 2836 - The Patients Over Profits Act H.R. 4409 - The Fair Pharmacies for Federal Employees Act of 2025 Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues. P.L. 119-21, The One Big, Beautiful Bill Act S. 2099, The Restore Prescription Drugs Discount Act Issues related to organized retail crime. H.R. 2853/S. 1404, The Combatting Organized Retail Crime Act S. 2068 - The End Prescription Drugs Ads Now Act H.R. 3789 - The Drug-price Transparency for Consumers Act of 2025"
You can find more data on corporate lobbying on Quiver Quantitative.
CVS Congressional Stock Trading
Members of Congress have traded $CVS stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $CVS stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 05/15.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CVS Insider Trading Activity
CVS insiders have traded $CVS stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CVS stock by insiders over the last 6 months:
- LARRY ROBBINS has made 0 purchases and 6 sales selling 3,750,000 shares for an estimated $253,695,413.
- ANNE A. FINUCANE sold 7,500 shares for an estimated $532,650
- GUY P SANSONE purchased 1,570 shares for an estimated $100,009
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CVS Hedge Fund Activity
We have seen 784 institutional investors add shares of CVS stock to their portfolio, and 904 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 14,716,719 shares (+47.6%) to their portfolio in Q2 2025, for an estimated $1,015,159,276
- BLACKROCK, INC. added 10,093,204 shares (+9.0%) to their portfolio in Q2 2025, for an estimated $696,229,211
- CAPITAL RESEARCH GLOBAL INVESTORS removed 9,510,578 shares (-50.8%) from their portfolio in Q2 2025, for an estimated $656,039,670
- HARRIS ASSOCIATES L P removed 5,151,769 shares (-85.9%) from their portfolio in Q2 2025, for an estimated $355,369,025
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 3,750,000 shares (-31.4%) from their portfolio in Q2 2025, for an estimated $258,675,000
- HOLOCENE ADVISORS, LP removed 3,554,232 shares (-60.0%) from their portfolio in Q2 2025, for an estimated $245,170,923
- JPMORGAN CHASE & CO added 3,440,623 shares (+14.7%) to their portfolio in Q2 2025, for an estimated $237,334,174
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CVS Analyst Ratings
Wall Street analysts have issued reports on $CVS in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/14/2025
- Goldman Sachs issued a "Buy" rating on 10/14/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/26/2025
- Baird issued a "Outperform" rating on 08/14/2025
- Jefferies issued a "Buy" rating on 06/30/2025
- Barclays issued a "Overweight" rating on 06/02/2025
- Truist Securities issued a "Buy" rating on 05/12/2025
To track analyst ratings and price targets for CVS, check out Quiver Quantitative's $CVS forecast page.
CVS Price Targets
Multiple analysts have issued price targets for $CVS recently. We have seen 12 analysts offer price targets for $CVS in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Erin Wright from Morgan Stanley set a target price of $89.0 on 10/14/2025
- Scott Fidel from Goldman Sachs set a target price of $91.0 on 10/14/2025
- Ann Hynes from Mizuho set a target price of $88.0 on 10/09/2025
- Stephen Baxter from Wells Fargo set a target price of $103.0 on 10/07/2025
- Lance Wilkes from Bernstein set a target price of $77.0 on 09/05/2025
- Andrew Mok from Barclays set a target price of $87.0 on 09/04/2025
- Sarah James from Cantor Fitzgerald set a target price of $78.0 on 08/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
